CH \$190.00 850934

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM463146

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE: RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Western Alliance Bank	FORMERLY Bridge Bank, National Association	02/22/2018	Chartered Bank: UNITED STATES

RECEIVING PARTY DATA

Name:	Good Start Genetics, Inc.			
Street Address:	237 Putnam Avenue			
City:	Cambridge			
State/Country:	MASSACHUSETTS			
Postal Code:	02139			
Entity Type:	Corporation: DELAWARE			

PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Serial Number:	85093437	GOODSTART GENETICS
Serial Number:	85599068	GOODSTART SELECT
Serial Number:	85599066	GSG LABSOLUTIONS
Serial Number:	85599063	GSG SOLUTIONS
Serial Number:	85599051	GIVING THE NEXT GENERATION A GOOD START
Serial Number:	85600801	HELPING TO GIVE THE NEXT GENERATION A GO
Serial Number:	85683029	GOODSTART TESTSELECT

CORRESPONDENCE DATA

Fax Number: 6178568201

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 617-856-8483

Email: ip@brownrudnick.com
Correspondent Name: Thomas C. Meyers
Address Line 1: Brown Rudnick LLP
Address Line 2: One Financial Center

Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	029258/1
-------------------------	----------

NAME OF SUBMITTER: Thomas C. Meyers

TRADEMARK REEL: 006278 FRAME: 0197

SIGNATURE:	/Thomas C. Meyers/
DATE SIGNED:	02/23/2018
Total Attachments: 8	
source=Release of IP#page1.tif	
source=Release of IP#page2.tif	
source=Release of IP#page3.tif	
source=Release of IP#page4.tif	
source=Release of IP#page5.tif	
source=Release of IP#page6.tif	
source=Release of IP#page7.tif	
source=Release of IP#page8.tif	

TRADEMARK REEL: 006278 FRAME: 0198

RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Release of Intellectual Property Security Agreement (this "Release") is made as of February 22, 2018, and granted by WESTERN ALLIANCE BANK, as successor in interest to BRIDGE BANK, NATIONAL ASSOCIATION (the "Lender"), in its capacity as lender pursuant to that certain Loan and Security Agreement, dated December 21, 2012 (together with all amendments and modifications, if any, from time to time thereafter made thereto, the "Loan Agreement") by and between Good Start Genetics, Inc., a Delaware corporation ("Grantor") and the Lender. Capitalized terms used herein have the meanings attributed thereto in the Loan Agreement unless otherwise defined herein.

WHEREAS, pursuant to the Loan Agreement, a security interest (the "Security Interest") was granted by the Grantor to the Lender in certain collateral, including the Intellectual Property Collateral (as defined in the Intellectual Property Security Agreement (hereinafter defined));

WHEREAS, pursuant to the terms and conditions of that Intellectual Property Security Agreement, dated as of April 25, 2013 (the "Intellectual Property Security Agreement"), between the Grantor and the Lender, which was recorded with the United States Patent and Trademark Office on April 20, 2013, on Reel 030315 Frame 0963, and which was recorded with the United States Patent and Trademark Office on April 30, 2013, on Reel 005026 Frame 0092, the Grantor granted to the Lender a Security Interest in all right, title, and interest of Grantor in, to and under the Intellectual Property Collateral; and

WHEREAS, the Lender now desires to terminate, cancel, discharge and release the entirety of its Security Interest in the Intellectual Property Collateral.

NOW, THEREFORE, for good and valuable consideration including the satisfaction of all obligations, indebtedness and liabilities secured by the Intellectual Property Collateral pursuant to the Loan Agreement, the receipt and adequacy of which are hereby acknowledged, and upon the terms set forth in this Release, the Lender hereby agrees as follows:

- 1. <u>Definitions</u>. The term "Intellectual Property Collateral" shall have the meaning provided by reference in the Intellectual Property Security Agreement, and shall include, without limitation, the Copyrights described in Exhibit A hereto, the Trademarks described in Exhibit B hereto, and the Patents and Patent Applications described in Exhibit C hereto.
- 2. Release of Security Interest. The Lender hereby terminates the Intellectual Property Security Agreement and hereby terminates, cancels, discharges and releases its Security Interest in the Intellectual Property Collateral, in each case without warranty or recourse. If and to the extent the Lender has acquired any right, title or interest in, to or under any of the Intellectual Property Collateral, then the Lender hereby assigns, transfers, conveys and delivers such right, title or interest to the Grantor, in each case without warranty or recourse.
- 3. <u>Further Assurances.</u> The Lender shall take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, with cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), in each case reasonably requested by the Grantor in writing to more fully and effectively effectuate the purposes of this Release, in each case at the Grantor's sole expense.
- 4. <u>Governing Law.</u> This Release shall be construed in accordance with and governed by the law of the State of California without regard to its conflicts of laws principles.

[Signature Page Follows]

IN WITNESS WHEREOF, the Lender has caused this Release to be executed and delivered by its duly authorized officer as of the date first set forth above.

LENDER:

WESTERN ALLIANCE BANK, as successor in interest to BRIDGE BANK, NATIONAL ASSOCIATION

Ву: __

Name:

Title:

Exhibit A COPYRIGHTS

None.

(Remainder of the page is blank.)

3

EXHIBIT B TRADEMARKS

Application Number	Mark Filing Da		
Serial No. 85093437 Registration No. 4096815	GOOD START GENETICS	27-July-2010	
Serial No. AU1405764	GOOD START GENETICS	27-Jan-2011	
Serial No. CA1512721	GOOD START GENETICS	26-Jan-2011	
Serial No. CN9066430	GOOD START GENETICS	27-Jan-2011	
Serial No. EC9689522	GOOD START GENETICS	27-Jan-2011	
Serial No. JP2011-005125	GOOD START GENETICS	27-Jan-2011	
Serial No. 85/599068	GOODSTART SELECT	16-Apr-2012	
Serial No. 85/599066	GSG LABSOLUTIONS	16-Apr-2012	
Serial No. 85/599063	GSG SOLUTIONS	16-Apr-2012	
Serial No. 85/599051	GIVING THE NEXT GENERATION A GOOD START	16-Apr-2012	
Serial No. 85/600801	HELPING TO GIVE THE NEXT GENERATION A GOOD START	18-Apr-2012	
Serial No. 85/683029	GOODSTART TESTSELECT	20-Jul-2012	

(Remainder of the page is blank.)

EXHIBIT C PATENTS and PATENT APPLICATIONS Patent Applications:

Patent Application Number	Country	Filing Dat	e Title	Attorney Docket Number	Status	Priority
61/426,817	US	23-Dec-10	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE- 001/00US	Expired	open e energenigischen Geschlichte und Schichte enem Dad
13/081,660	US	07-Apr-11	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE- 001/01US	Pending	61/426,817
PCT/US11/65 098	РСТ	15-Dec-11	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE- 001/01WO	Pending	61/426,817; 13/081,660
61/174,470	US	30-Apr-09	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/00US	Expired	
61/178,923	US	15-May-09	METHODS AND COMPOSITIONS FOR ENHANCING THE SENSITIVITY OF NUCLEIC ACID ANALYSIS	GSGE- 003/00US	Expired	The Act of the Control of the Contro
61/179,358	US	18-May-09	METHODS AND COMPOSITIONS FOR REDUCING DIAGNOSTIC ERRORS ASSOCIATED WITH BIAS IN PREPARATIONS OF NUCLEIC ACIDS	GSGE- 004/00US	Expired	
61/182,089	US	28-May-09	EVALUATIONS OF TARGET LENGTH IN NUCLEIC ACID CAPTURE-BASED ASSAYS	OSGE- 005/00US	Expired	i South State of the State of t

TRADEMARK REEL: 006278 FRAME: 0203

PCT/US16/01 293	РСТ	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01WO	Nationalized	61/178,923; 61/179,358; 61/182,086; 61/174,470.
2010242073	AU	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01AU	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/0 01293
2760439	CA	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01CA	Published	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/0 01293
10770071.8	БР	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01EP	Published	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/0 01293
216054	IL	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/011L	Pending.	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/0 01293
8063/CHENP /2011	IN	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01/N	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2016/0 01293
2012-508490	JP 91	30-Apr-10	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01JP	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/0 01293
13/266,862	US	28-Oct-11	METHOD FOR REDUCING REPRESENTATIONAL BIAS IN MULTIPLEX AMPLIFICATION OF NUCLEIC ACIDS	GSGE- 002/01US	Pending	61/178,923; 61/179,358; 61/182,086; 61/174,470; PCT/US2010/0 01293

61/789,164	US	15-Mar-13	METHODS AND COMPOSITIONS FOR EVALUATING GENETIC MARKERS	GSGE- 002/02US	Pending	
13/077,169	US	31-Mar-11	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE- 006/00US	Pending	
PCT/US12/29 790	PCT	20-Mar-12	METHODS FOR MAINTAINING THE INTEGRITY AND IDENTIFICATION OF A NUCLEIC ACID TEMPLATE IN A MULTIPLEX SEQUENCING REACTION	GSGE- 006/01WO	Pending	13/077/169
13/439,508	US	4-Apr-12	SEQUENCE ASSEMBLY	GSGE- 007/00US	Issued; US 8,209,130	
13/494,616	US	13-Jun-12	SEQUENCE ASSEMBLY	GSGE- 007/01US	Pending	13/439,508
PCT/US13/33 435	US	22-Mar-13	SEQUENCE ASSEMBLY	GSGE- 007/01WO	Pending	13/439,508 and 13/494,616
61/548,073	US	17-Oct-11	ANALYSIS METHODS	GSGE- 008/00US	Expired	
13/616,788	US	14-Sept-12	ANALYSIS METHODS	GSGE- 008/01US	Pending	61/548,073
PCT/US12/55 362	PCT	14-Sept-12	ANALYSIS METHODS	GSGE- 008/01WO	Pending	61/548,073
61/624,778	US	16-Apr-12	PERFORMANCE OF CAPTURE REACTIONS	GSGE- 009/00US	Pending	idariin anada aa aa aa ah
13/448,961	US	17-Apr-12	CAPTURE REACTIONS	GSGE- 009/01US	Pending	61/624,778
61/621,779	ĽS	9-Apr-12	VARIANT DATABASE	GSGE- 010/00US	Pending	
13/667,575	US	2-Nov-12	VARIANT DATABASE	GSGE- 010/01US	Pending	61/621,779
PCT/US13/32 885	US	19-Mar-13	VARIANT DATABASE	GSGE- 010/01WO	Pending	61/621,779 and 13/667,575
61/707,495	US	28-Sept-12	OPTIMIZATION OF BIOMARKER NUMBERS IN SCREENING ASSAYS	GSGE- 012/00US	Pending	

13/488,142	LIS	4-Jun-12	DETERMINING THE CLINICAL SIGNIFICANCE OF VARIANT SEQUENCES	GSGE- 011/00US	Pending
61/723,550	US	7-Nov-12	METHODS AND SYSTEMS FOR IDENTIFYING CONTAMINATION IN SAMPLES	GSGE- 013/00US	Pending
61/723,508	US	7-Nov-12	VALIDATION OF GENETIC TESTS	GSGE- 014/00US	Pending
61/784,624	US	14-Mar-13	METHODS FOR ANALYZING NUCLEIC ACIDS	GSGE- 016/00US	Pending

(Remainder of the page is blank.)

62968900

8